Intervention not reported
Clinical outcomes: improvement in iridocyclitis at 6 months · people residing in communities endemic for onchocerciasis
It is very uncertain whether the intervention changes clinical outcomes: improvement in iridocyclitis at 6 months (very low certainty).
1 finding from 1 review
Intervention not reported
Clinical outcomes: improvement in punctate keratitis at 6 months · people residing in communities endemic for onchocerciasis
It is very uncertain whether the intervention changes clinical outcomes: improvement in punctate keratitis at 6 months (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people residing in communities endemic for onchocerciasis
The intervention probably leads to lower adverse events (moderate certainty).
1 finding from 1 review
no estimate extracted
2010 participants
Moderate
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · CNV in people with pathologic myopia
1 finding from 1 review
Gain 3+ lines of visual acuity at 1 year · CNV in people with pathologic myopia
Anti‐VEGF probably leads to higher gain 3+ lines of visual acuity at 1 year compared with control (moderate certainty).
1 finding from 1 review
Change in central macular thickness at 1 year · CNV in people with pathologic myopia
1 finding from 1 review
CNV angiographic closure at 1 year · CNV in people with pathologic myopia
Anti‐VEGF showed no clear difference in CNV angiographic closure at 1 year compared with control (low certainty).
1 finding from 1 review
Serious systemic adverse events · CNV in people with pathologic myopia
It is very uncertain whether anti‐VEGF changes systemic serious adverse events compared with control (very low certainty).
1 finding from 1 review
Adverse events (ocular problems) · CNV in people with pathologic myopia
It is very uncertain whether anti‐VEGF changes ocular adverse events compared with control (very low certainty).
1 finding from 1 review
Quality of life · CNV in people with pathologic myopia
1 finding from 1 review
Intervention not reported
Recurrence of pterygium ( · individuals with pterygium
The intervention may leads to lower recurrence of pterygium ( (low certainty).
1 finding from 1 review
RR 0.47 [0.27, 0.82]
Studies not reported
Low
Intervention not reported
Occurrence of complication · individuals with pterygium
The intervention may leads to higher occurrence of complication (low certainty).
1 finding from 1 review
RR 1.92 [1.22, 3.02]
Studies not reported
Low
Intervention not reported
Operating time · individuals with pterygium
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Mean change in BCVA in ETDRS letters at 1 year (number of letters) · people with age‐related macular degeneration
The intervention showed no clear difference in mean change in BCVA in ETDRS letters at 1 year (number of letters) (high certainty).
1 finding from 1 review
Intervention not reported
Gain of ≥ 15 letters of BVCA at 1 year · people with age‐related macular degeneration
The intervention showed no clear difference in gain of ≥ 15 letters of BVCA at 1 year (high certainty).
1 finding from 1 review
Intervention not reported
Absence of fluid on optical coherence tomography (OCT) at 1 year · people with age‐related macular degeneration
The intervention showed no clear difference in absence of fluid on optical coherence tomography (OCT) at 1 year (high certainty).
1 finding from 1 review
Intervention not reported
Quality‐of‐life measures at 1 year (National Eye Institute‐Visual Function Questionnaire [NEI‐VFQ]) · people with age‐related macular degeneration
The intervention showed no clear difference in quality‐of‐life measures at 1 year (National Eye Institute‐Visual… (high certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ serious systemic events at 1 year · people with age‐related macular degeneration
The intervention showed no clear difference in adverse events ‐ serious systemic events at 1 year (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ serious ocular events at 1 year · people with age‐related macular degeneration
The intervention showed no clear difference in adverse events ‐ serious ocular events at 1 year (moderate certainty).
1 finding from 1 review
Recurrence of pterygium · people with primary or recurrent pterygium
It is very uncertain whether summary of findings for conjunctival autograft changes recurrence of pterygium compared with amniotic membrane transplant (very low certainty).
2 findings from 1 review